A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Upadacitinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors AbbVie
- 19 May 2017 Status changed from recruiting to active, no longer recruiting.
- 02 May 2017 Planned End Date changed from 24 Jan 2019 to 25 Jan 2019.
- 14 Apr 2017 Planned End Date changed from 1 Mar 2018 to 24 Jan 2019.